• Overview
  • Eligibility
  • More info
  • Locations

Phase III Randomized Study of Cisplatin and Etoposide With or Without Epirubicin and Cyclophosphamide for Extensive Stage Small Cell Lung Cancer (NCT00003606)

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether combination chemotherapy with or without epirubicin and cyclophosphamide is more effective in treating patients with extensive stage small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without epirubicin and cyclophosphamide in treating patients who have extensive stage small cell lung cancer.
  • Drug: cisplatin
    • Drug: cyclophosphamide
      • Drug: epirubicin hydrochloride
        • Drug: etoposide
          • Radiation: radiation therapy
            Ages eligible for Study
            18 Years to 75 Years
            Genders eligible for Study
            All
            Accepts Healthy Volunteers
            No
            OBJECTIVES: I. Compare the overall survival and survival without recurrence of patients with extensive stage small cell lung cancer after receiving cisplatin and etoposide with or without epirubicin and cyclophosphamide. II. Compare the relative dose and intensity of cisplatin and etoposide between the two groups of patients. III. Compare the complete and objective response rate and quality of life of these patients. IV. Compare the toxic effects of these 2 regimens in these patients.

            OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms. Arm I: Patients receive etoposide IV on days 1 and 3 and cisplatin IV on day 2. Arm II: Patients receive etoposide and cisplatin as in arm I, plus epirubicin IV on day 1 and cyclophosphamide IV on days 1 and 3. Treatment is repeated in both arms every 28 days for up to 6 courses. Patients who achieve a partial or complete response receive cerebral and/or thoracic radiotherapy. Patients with residual tumor may receive oral etoposide for 3 of every 4 weeks. Patients are followed every 3 months.

            PROJECTED ACCRUAL: A total of 216 patients will be accrued for this study within 2.5 years.

            1 locations

            France (1)
            • Hopital Arnaud de Villeneuve
              Not specified
              Montpellier, France, 34295
            Status:
            unknown
            Type:
            Interventional
            Phase:
            Start:
            28 February, 1998
            Updated:
            05 February, 2009
            Participants:
            216
            A girl giving information about available additional trials.

            FindMeCure helps you find, understand and join clinical trials from all over the world.

            There are more clinical trials for your condition!